HEALTH TECHNOLOGY

Ambra Health Collaborates with Arterys to Accelerate clinical-grade AI Imaging Capabilities

Ambra Health | May 05, 2021

Ambra Health, the leading cloud-based medical image management suite provider, today announced a collaboration with Arterys, the world's leading vendor-neutral AI platform. The collaboration enables Ambra Health to connect directly with the Arterys platform for smooth interoperability, accelerating efforts to deliver innovative clinical-grade AI applications to providers.

Arterys is a medical imaging AI platform and marketplace that allows providers to seamlessly integrate AI clinical applications with current imaging data workflows. Arterys has seven FDA-cleared AI solutions, including Cardio AI, Lung AI, and Neuro AI, making it simple for doctors to integrate AI into their workflows from a single interface.

The Ambra suite consolidates various imaging systems with a single flexible, customizable, and interoperable cloud system that allows providers to safely access imaging data anytime, anywhere. Layering new AI applications within the Ambra platform results in a powerhouse of innovative workflows, opportunities for R&D, and long-term enhancements to patient care.

The collaboration is the latest example of Ambra Health's efforts to increase interoperability among AI solution providers. The company confirmed collaborations with CureMetrix, CuraCloud, and ImageBiopsy in late 2020.

About Ambra Health

Ambra Health is a software-as-a-service provider for medical data and image management. The Ambra cloud platform is intended to act as the foundation of imaging innovation and progress for healthcare professionals by being intuitive, flexible, scalable, and highly interoperable. It enables some of the biggest health systems in the world, including Memorial Hermann, Johns Hopkins Medicine, UC San Diego, and New York Presbyterian, as well as radiology practices, subspecialty practices, and life sciences organizations, to significantly enhance imaging and collaborative treatment workflows.

About Arterys

As the world's first and only internet platform for AI in medical imaging, Arterys is the industry leader. Their goal is to transform radiology to transform healthcare. The Arterys platform is entirely software-based, AI-powered, and FDA cleared, enabling clinical solutions that need little more than a web browser and an internet connection.
 

Spotlight

Gone are the days of vendor-specific imaging. Today’s leaders understand that optimum performance and efficiencies depend on strategies that leverage industry standards. The drive for early diagnoses, chronic disease, and the rising age of the population resulted in a growing demand for medical imaging services. This is pressur


Other News
HEALTH TECHNOLOGY

Base Business Solutions and Uniphore Partner to Bring Emerging Technology to Vietnam’s CX Industry

Uniphore | September 12, 2022

Base Business Solutions a leading provider of cloud and hosted customer experience and contact center solutions in Vietnam announced it has entered into a strategic partnership with Uniphore, the leader in Conversational AI and Automation. Through this partnership, BaseBS will be well positioned to enhance customer experiences, improve employee performance, and better understand customer insights to achieve superior business outcomes. As part of the agreement, BaseBS will offer customers Conversational AI and Automation capabilities across their initiatives around self-service and assisted service channels. Uniphore’s X platform is an integrated conversational AI and automation platform that combines automatic speech recognition (ASR) including the Vietnamese language, natural language processing (NLP), robotic process automation (RPA), emotion AI and knowledge AI that enterprises need in today’s tech-savvy customer era. These technology components translate into specific offerings for customers in the form of chatbots, voice bots, conversational analytics for quality automation, and customer analysis and agent guidance in real-time. The partnership will have far-reaching benefits for customers, employees, and organizations that will impact not only how they do business today as they continue to adjust to the current global situation, but also in the long term. Benefits include Personalized automated resolutions for customers thus bringing in time to value through Uniphore’s U Self Serve product Contact center employee productivity and efficiency will see a boost through U-Assist, a Uniphore product that can guide agents in real-time with in-call alerts, next-best-action and reduce their after-call work Businesses will be able to make data-driven decisions with smarter conversational analytics. Through Uniphore’s U Analyze solution, businesses can transform CX by analysing conversations from across platforms including voice, email, and text to increase effectiveness with omnichannel support and an integrated view of conversations to discover customers' intent and sentiments “BaseBS is extremely pleased to partner with Uniphore on our journey to bring emerging technology such as Artificial Intelligence (AI), machine learning and automation to the CX industry in Vietnam. With Uniphore’s conversational AI and automation platform we will be better positioned to enable our customers to personalize conversations, enhance contact center employee productivity and use conversation insights for better decisions.” Mr. Pham Xuan Phuc, Vice President, Base Business Solutions “We are excited about the partnership with BaseBS as they look ahead to strengthen and offer more comprehensive CX solutions for contact centers in the local market,” said Mr. Gokul Gopalakrishnan, Senior Vice President & Business Head, Asia, Uniphore. “We see a natural synergy with BaseBS thereby creating strong joint value propositions, go-to-market strategies, and unmatched CX solutions for enterprises, and experiences for customers.” BaseBS is part of Uniphore’s Reseller partner program. The program provides partners with the necessary resources to leverage cutting-edge technology and enhance their portfolio and offerings resulting in increased revenue growth. Uniphore also launched the Unite App Alliance Partner Program, which enables value-driven collaboration and cross-selling for participating Independent Software Vendors (ISV) to have greater access to and involvement in shaping the direction and strategy of tomorrow’s conversational AI and automation, and supporting CX technology innovation. About Uniphore Uniphore is the global leader in Conversational Automation. Every day, billions of conversations take place across industries — customer service, sales, HR, education and more. Whether they are human to human, human to machine or machine to machine, conversations are at the heart of everything we do, and the new currency of the enterprise. At Uniphore, we believe companies that best understand and take action on those conversations will win. We have built the most comprehensive and powerful conversational automation platform that combines conversational AI, workflow automation and RPA (Robotic Process Automation) with a business user friendly UX in a single integrated platform to transform and democratize customer experiences across industries. Follow our blog and connect with us on LinkedIn, Twitter, Facebook, and Instagram. About Base Business Solutions Founded in 2005, BaseBS is one of the leading companies providing cloud and hosted customer experience and contact center solutions in Vietnam. BaseBS offers tailor-made CX solutions to hyper-scale and large enterprise clients that empower them to achieve customer service excellence and gain competitive advantages in the market. We are honored as Advanced Technology Partner of Cisco in implementing Call Center & Contact Center infrastructure. A combination of comprehensive industry expertise, a professional team and leading-edge technologies enables our clients to modernize their customer journey and maximize business productivity. Our portfolio is active in a wide range of business areas such as Banking & Finance, Insurance, Retail, Logistics, Hospitality, Medical & Healthcare, etc.

Read More

HEALTH TECHNOLOGY

Health Care Software Provider GoMeyra Announces Partnership with Visit Healthcare

GoMeyra | July 20, 2022

GoMeyra, a cloud software company dedicated to providing innovative, real-time software for the health care industry, announces partnership with Visit Healthcare, a nationwide turnkey mobile medical provider. GoMeyra’s laboratory information management system (LIMS) will now power the health care company’s onsite lab diagnostic testing, immunizations and other medical solutions for enterprise-level clients. “Our need for a reliable technology partner has increased tremendously in the past few years, and the portals we have been using have limited flexibility, especially as we move into mobile medical services beyond COVID. GoMeyra has already bolstered our mobile capabilities with its versatile technology that has the ability to customize to our clients’ changing needs. Their team is quick to respond and the reporting process is simple. We also work with many of the same clients, so the transition to a new system has been easy. They are a great match for us” Visit Healthcare CEO, Olympia Bliss GoMeyra’s Laboratory Information Management Solution is a revolutionary, cloud-based software platform solution that empowers labs, health care facilities and medical practices to achieve unprecedented processing times for COVID-19 RT-PCR, rapid PCR, antigen, antibody and serology testing while automating procedures and managing samples faster and more accurately. New testing panels will be added in the very near future. “Visit Healthcare is growing fast, and like many growing companies, they need technology to be more agile and evolve with their business. Many companies, when they start out, don’t realize how important this flexibility is until they outgrow their current system. We offer medical practitioners a painless transition and peace of mind so they can focus on operations and not worry about their technology needs,” added GoMeyra Founder and Chief Executive Officer, Jaswant S. Tony. Visit Healthcare will also have access to GoVirtual Clinic, GoMeyra’s newly launched telehealth platform, which is fully integrated with GoMeyra LIMS. GoVirtual Clinic is a next-generation platform that includes a suite of solutions for medical professionals to conduct virtual patient appointments while comprehensively managing patient care and related electronic health records. The first phase of the platform features ways to seamlessly schedule and manage virtual testing appointments, order test kits, monitor online waiting rooms, conduct virtual appointments, and share test results with patients in real-time. For product demonstrations, contact info@GoMeyra.com or call (844) 203-3960. About GoMeyra GoMeyra is a trusted technology partner providing innovative, real-time software solutions that simplifies processes and delivers unparalleled customer service for the health care industry. GoMeyra’s premiere product, GoMeyra LIMS, is an automated, customizable laboratory information management system that improves workflow efficiencies, enabling laboratories, medical providers, employers and enterprise organizations to process lab tests and deliver patient results with unprecedented speed. GoMeyra Network, a unique built-in feature, allows independent labs across the country to collaborate and compete with larger diagnostic providers. About Visit Healthcare Visit Healthcare, a nationwide turnkey mobile medical provider, works with states, counties, government agencies, schools, and private industry on rapid response healthcare solutions. With a background in emergency response, Visit Healthcare has a proven ability to mobilize health care workers across the country in a very short period of time and currently operates testing and/or vaccination services in more than 26 states. With healthcare professionals and numerous CLIA-certified high-complexity laboratories at the ready, Visit Healthcare plays an active role in additional health care services including flu​ clinics, telehealth, and molecular testing beyond COVID-19.

Read More

HEALTH TECHNOLOGY

Cardinal Health Announces Governance Enhancements and Shareholder Value Creation Initiatives

Cardinal Health | September 07, 2022

Cardinal Health announced initiatives aimed at positioning the Company for long-term success, building on Cardinal Health's previously announced growth plans. These initiatives have benefited from input received from Elliott Investment Management L.P. In connection with these initiatives, Elliott has also entered into a cooperation agreement with Cardinal Health, and Elliott's Steven Barg will join the Company's Board of Directors. As part of Cardinal Health's ongoing commitment to Board refreshment and the initiatives announced today, the Governance and Sustainability Committee of the Board has recommended and the Board has approved the appointment of four new independent directors: Steven Barg, Michelle Brennan, Sujatha Chandrasekaran and Christine Mundkur. With these immediate appointments, Cardinal Health's Board will be made up of 15 Directors, 14 of whom are independent under the Company's director independence standards. Two existing Directors – Dean Scarborough and John Weiland – have announced their intentions to conclude their Board service at the end of their previously elected terms this fall and will not stand for re-election at Cardinal Health's 2022 Annual Meeting, resulting in a 13-member Board. Following the Annual Meeting, Cardinal Health's Board will consist of 54% women and 23% racially or ethnically diverse individuals. Cardinal Health's Board has also formed a new Board committee, the Business Review Committee, to support a comprehensive review of the Company's strategy, portfolio, capital-allocation framework, and operations with the goal of maximizing Cardinal Health's potential for the benefit of all stakeholders. The Business Review Committee will be chaired by Chief Executive Officer Jason Hollar; Mr. Barg and Akhil Johri will also serve on the Committee. The Committee, with the assistance of the Company's legal and financial advisors, will make recommendations to the full Board. The Company expects to conduct an investor day in the first half of calendar 2023 to share the Board's conclusions and to provide additional guidance. "We'd like to thank Dean and John for their service to the Board. We're grateful for their leadership and contributions and wish them both the very best. We're pleased to welcome Steven, Michelle, Sujatha and Christine to the Board and believe the Company and our many stakeholders will benefit from their mix of experience, skills and leadership. We are also pleased with Elliott's confidence in, and commitment to, the go-forward long-term potential of Cardinal Health. Our Board looks forward to receiving the recommendations of the Business Review Committee and updating the market in due course, as Jason and his leadership team chart a path to deliver upon our mission for our customers and employees and drive value creation for our shareholders." Gregory Kenny, Independent Chairman of the Board of Cardinal Health "Cardinal Health's leadership team is focused on creating value for all our stakeholders, and the newly initiated Business Review Committee, as well as the new expertise and experience being added to our Board, are critical steps in this process," said Mr. Hollar, Cardinal Health's Chief Executive Officer. "I look forward to working with the Board, including our four new directors, to optimize our strategy, structure, and operations as we position Cardinal Health for long-term success." Elliott Senior Portfolio Manager Marc Steinberg said, "Our discussions with Jason and the Board have been positive and productive, and we are pleased to have worked collaboratively to reach this agreement. Cardinal Health plays a mission-critical, market-leading role in the global healthcare system, and we have been encouraged by the Company's openness to taking actions necessary to ensuring that Cardinal Health realizes its full potential. We are confident that the initiatives announced today will drive meaningful shareholder value creation, and we look forward to continuing our collaboration with the Company." Michelle Brennan is Chair of Connect Healthcare Council for Pioneering Collective and serves on the Board of Coupa Software. Ms. Brennan spent more than 30 years at Johnson & Johnson, a leader in the field of medical devices, pharmaceutical, and consumer packaged goods, where she focused on driving growth, optimization and business transformation across diverse businesses and geographies. Most recently, Ms. Brennan served as the Global Value Creation Leader for Johnson & Johnson and as a member of the company's Medical Device Executive Leadership Team responsible for the division's value creation through cost management initiatives. Prior to that, Ms. Brennan held a number of positions at Johnson & Johnson, including Company Group Chair, Medical Devices (EMEA); President, Enterprise Standards & Productivity; Worldwide President, Ethicon Energy; as well as a variety of sales and marketing positions for other Johnson & Johnson divisions. Throughout her time at Johnson & Johnson, Ms. Brennan held significant board roles for the company, including Chairman of the Board for Medtech Europe Trading Association. She was previously a member of the UK's Office of Life Sciences Council and Chairman of the Council's Health Technology Partnership Committee. Ms. Brennan holds a B.S. from the University of Kansas. Sujatha Chandrasekaran, also known as Suja, is an advisor and independent consultant in the research and technology sectors. She currently serves on the Board of American Eagle Outfitters as well as private companies including Agendia, a molecular diagnostics company, and Blume Global, a digital supply chain platform company. Ms. Chandrasekaran has more than 25 years of experience in technology and leadership roles across the healthcare, consumer packaged goods and retail industries. Most recently, Ms. Chandrasekaran was Senior EVP & Chief Digital and Information Officer at CommonSpirit Health, one of the largest non-profit health systems in the US. Prior to that, she held a number of senior executive roles at several Fortune 500 multinational companies, including Global Chief Information Officer for Kimberly-Clark; SVP, Global Chief Technology and Data Officer for Walmart; as well as a number of C-level roles at The Timberland Company, PepsiCo and Nestlé SA. Ms. Chandrasekaran has a strong track record of delivering significant value to customers and organizations by leading global technology, supply chain and digital transformation initiatives. In 2022, Ms. Chandrasekaran was recognized by Modern Healthcare as one of the Top 25 Women Leaders in Healthcare. She was previously a Director of Symphony Technology Group and a Director of Barry Callebaut AG as well as a Member of Advisory Board at Atmio Inc. Ms. Chandrasekaran holds an Executive Development Education Certificate from London Business School; a Master of Business Systems/M.B.A. from Monash University in Melbourne, Australia; and a B.Eng. from the University of Madras, India. Christine Mundkur most recently served as Chief Executive Officer and Non-Voting Chairman of the Board of Directors for Impopharma Inc, a developer of complex formulations focused on inhalation pharmaceutical products. Ms. Mundkur currently serves on the Boards of Lupin Limited and MannKind Corporation. While at Impopharma, she led the transition of the company from a successful clinical research organization into a generic pharmaceutical inhalation development company. She also held leadership positions as President and Chief Executive Officer for North America for Sandoz, Inc. Earlier, she served as Chief Executive Officer of Barr Laboratories, Inc. Ms. Mundkur started her career at Barr as quality and regulatory counsel. In addition, she served as a strategic advisor to clients on generics, 505(b)2, biosimilars and NDA business strategies. Ms. Mundkur holds a J.D. from the St. Louis University School of Law and a B.S. from St. Louis University. About Cardinal Health Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities. With 50 years in business, operations in more than 30 countries and approximately 44,000 employees globally, Cardinal Health is essential to care.

Read More

HEALTH TECHNOLOGY

Cue Health Provides Enhanced Care & Protection for Immunocompromised Populations & Clinical Care Teams at Fresenius Kidney Care

Cue Health Inc. | August 25, 2022

Cue Health Inc. a healthcare technology company announced a new collaboration with Fresenius Kidney Care to provide the most accurate* COVID-19 self-test to certain patients and clinical care teams. People who are immunocompromised have been disproportionately affected by COVID-19 throughout the pandemic and remain highly dependent on measures that reduce the likelihood of infections, including vaccination. Cue can be used by vulnerable patient populations and their care partners to detect and treat COVID-19 early, often before complications arise and hospitalization is required. This is especially important in remote locations where timely and accurate results are critical for making clinical treatment decisions. Fresenius Kidney Care in Hawaii, Alaska, Puerto Rico, Guam, and Saipan will use the Cue Health Monitoring System and Cue COVID-19 Test to screen employees and test symptomatic immunocompromised patients in-center and at-home. "This is a great example of how Fresenius Kidney Care is seeking out the best technologies to ensure we do everything we can to protect our vulnerable patient population from COVID-19," said Ines Dahne-Steuber, President of Spectra Laboratories, a Fresenius Medical Care company providing laboratory diagnostics to dialysis centers across the country. "This collaboration with Cue will help us provide patients with greater access to high-quality timely diagnosis and care in our effort to improve health outcomes while lowering costs." Fresenius Kidney Care operates more than 2,600 dialysis centers in the U.S., providing more than 200,000 patients annually with services that include at-home peritoneal dialysis, at-home hemodialysis, in-center hemodialysis, and additional clinical care resources. "By utilizing Cue's platform, Fresenius Kidney Care can continue to provide its life-saving services to immunocompromised patients with confidence they are using the most accurate COVID-19 self-test. We treat accuracy as non-negotiable so healthcare-affiliated organizations across the country can continue to trust Cue for their testing needs in high-stakes environments." Ayub Khattak, Chairman and CEO of Cue Health Fresenius Kidney Care is one of the growing number of healthcare-affiliated organizations and internationally-recognized hospital systems throughout the U.S working with Cue to transform how diagnostic healthcare is delivered to close gaps in the patient journey and drive improved health outcomes. Cue is used in many other point-of-care settings such as Johns Hopkins Medicine and Mayo Clinic, by world-class organizations across the country, including Google, the National Basketball Association, and Major League Baseball, and in homes. Cue's test uses molecular nucleic acid amplification technology (NAAT) providing lab-quality results directly to connected mobile devices in 20 minutes. The test can detect all known COVID-19 variants and subvariants of concern - including Omicron, BA.4, and BA.5 - and can be used on adults and children (age 2 years and over for over-the-counter (OTC) / home use and under 2 for professional use), with or without symptoms. About Cue Health Cue Health is a healthcare technology company that makes it easy for individuals to access health information and places diagnostic information at the center of care. Cue Health enables people to manage their health through real-time, actionable, and connected health information, offering individuals and their healthcare providers easy access to lab-quality diagnostics anywhere, anytime, in a device that fits in the palm of the hand. Cue Health's first-of-its-kind COVID-19 test was the first FDA-authorized molecular diagnostic test for at-home and over-the-counter use without a prescription and physician supervision. Outside the United States, Cue Health has received the CE mark in the European Union, Interim Order authorization from Health Canada, regulatory approval from India's Central Drugs Standard Control Organization, and PSAR authorization from Singapore's Health Sciences Authority. Cue was founded in 2010 and is headquartered in San Diego.

Read More

Spotlight

Gone are the days of vendor-specific imaging. Today’s leaders understand that optimum performance and efficiencies depend on strategies that leverage industry standards. The drive for early diagnoses, chronic disease, and the rising age of the population resulted in a growing demand for medical imaging services. This is pressur

Resources